


[illegible]

-
- Chemical structure of a pyridine derivative. A benzene ring is substituted with a group Y-X at the para position and a pyridine ring at the other para position. The benzene ring has substituents R₃ and R₄. The pyridine ring has substituents A₁, A₂, A₃, and R₁.

wherein:



For R_7 ,

A_1 , A_2 and A_3 are independently CR₂ or N, provided that A_1 , A_2 and A_3 are not all N at the same time;

each R₂ is selected from the group consisting of hydrogen, optionally substituted alkyl, alkenyl, or alkynyl, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; or R₁ and R₂ are taken together with the carbon atoms to which they are attached to form a heterocyclic ring;

R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido,

acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R_7 is an optionally substituted alkyl;

R_8 is selected from the group consisting of alkyl, alkenyl, alkynyl, OR_9 , amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be optionally substituted, provided that R_8 is not OR_9 when R_1 is SO_2R_8 ; wherein

R_9 is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkali metal; and


X is one of O, S, NH, or CH_2 when Y is other than R_7 ; or

X is one of O, S, NH, CH_2 or absent when Y is R_7 ;

with the provisos that:

- 1) R_2 is not methoxy if R_3 is trifluoromethyl, R_6 is H, X is O and R_1 is SO_2CH_2Ph ;
- 2) R_2 is not NH_2 if R_1 is methylthio, X is O and two of A_1 , A_2 and A_3 are N;
- 3) R_2 is not methyl if R_1 is SO_2R_8 , wherein R_8 is methylphenyl, R_3 and R_4 are methoxy, X is S and two of A_1 , A_2 and A_3 are N;
- 4) R_2 is not CCl_3 if R_1 is CCl_3 , X is S and two of A_1 , A_2 and A_3 are N; or
- 5) R_1 and R_2 are not both NH_2 if X is O or S and two of A_1 , A_2 and A_3 are N.

2. A compound having the Formula II:



or a pharmaceutically acceptable salt, prodrug or solvate thereof,

wherein:

A₁, A₂ and A₃ are independently CR₂ or N, provided that A₁, A₂ and A₃ are not all N at the same time;

R₁ is selected from the group consisting an optionally substituted alkyl, amino, alkylthiol, C(O)R₈, SO₂R₈, OC(O)NH₂, 2-imidazolyl, 2-imidazolyl, 3-pyrazolyl, 5-isoxazolyl, and 3-(1,2,4)-triazolyl;

each R₂ is selected from the group consisting of hydrogen, optionally substituted alkyl, alkenyl, or alkynyl, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; or R₁ and R₂ are taken together with the carbon atoms to which they are attached to form a heterocyclic ring;

R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido, acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol; and

R₈ is selected from the group consisting of alkyl, alkenyl, alkynyl, OR₉, amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl,

Sub
B2
TOTAL 6998880

arylalkynyl, and arylalkylamino, all of which can be optionally substituted, provided that R_8 is not OR_9 when R_1 is SO_2R_8 ; wherein

R_9 is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkali metal; and

X is one of O, S, NH, or CH_2 ;

with the provisos that:

- 1) R_2 is not methoxy if R_5 is trifluoromethyl, R_6 is H, X is O and R_1 is SO_2CH_2Ph ;
- 2) R_2 is not NH_2 if R_1 is methylthio, X is O and two of A_1 , A_2 and A_3 are N;
- 3) R_2 is not methyl if R_1 is SO_2R_8 , wherein R_8 is methylphenyl, R_3 and R_4 are methoxy, X is S and two of A_1 , A_2 and A_3 are N;
- 4) R_2 is not CCl_3 if R_1 is CCl_3 , X is S and two of A_1 , A_2 and A_3 are N;
or
- 5) R_1 and R_2 are not both NH_2 if X is O or S and two of A_1 , A_2 and A_3 are N.

3. The compound of claim 2, wherein A_1 , A_2 and A_3 are each CR_2 ; or A_1 is N and A_2 and A_3 are CR_2 ; or A_3 is N and A_1 and A_2 are CR_2 ; or A_2 is N and A_1 and A_3 are CR_2 ; or A_1 and A_3 are N and A_2 is CR_2 .

4. The compound of claim 2, wherein R_1 is selected from the group consisting of an alkyl optionally substituted by halogen or hydroxy, $C(O)R_8$, SO_2R_8 , 2-imidazolynyl, 2-imidazolyl, 3-pyrazolyl, and 5-isoxazolyl, wherein R_8 is as defined in claim 2, provided that R_8 is not OR_9 when R_1 is SO_2R_8 .

5. The compound of claim 4, wherein R_8 is selected from the group consisting of alkyl, alkenyl, OR_9 , amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, and

These results are consistent with the idea that the effect of the intervention is to increase the number of people who are able to access the service, and that this is likely to be due to the fact that the intervention is designed to be a low-cost, low-intensity service that can be delivered in a community setting.

6. The compound of claim 2, wherein R_2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl, amino, hydroxyalkyl, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino.
7. The compound of claim 6, wherein R_2 is selected from the group consisting of hydrogen, alkyl, alkoxy, aminoalkyl and aminocarbonyl.
8. The compound of claim 2, wherein R_3 , R_4 , R_5 , and R_6 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, and cyano.
9. The compound of claim 8, wherein R_3 and R_4 are both hydrogen and R_5 and R_6 are independently selected from the group consisting of hydrogen, alkyl, halogen, haloalkyl, and nitro.
10. The compound of claim 2, wherein X is O or S.
11. The compound of claim 10, wherein X is O.
12. The compound of claim 2, wherein R_2 is hydrogen, X is O or S and R_1 is aminocarbonyl.
13. The compound of claim 2, wherein A_2 is CR_2 , wherein R_2 is other than H and A_1 and A_3 are each CH.


B4
cont

14. The compound of claim 2, wherein A_1 is N, A_2 is CR_2 , wherein R_2 is other than H and A_3 is CH.

15. The compound of claim 2, wherein A_3 is N, A_2 is CR_2 , wherein R_2 is other than H and A_1 is CH.

16. The compound of claim 2, wherein A_2 is N, A_1 is CR_2 , wherein R_2 is other than H, and A_3 is CH.

17. The compound of claim 2, having the Formula III:



or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein;

A_1 - A_3 , R_2 - R_6 , R_8 and X are as defined in claim 2.

S6
B4

18. The compound of claim 17, wherein A_1 , A_2 and A_3 are each CR_2 ; or A_1 is N and A_2 and A_3 are CR_2 ; or A_3 is N and A_1 and A_2 are CR_2 ; or A_2 is N and A_1 and A_3 are CR_2 ; or A_1 and A_3 are N and A_2 is CR_2 .

B4
cont

19. The compound of claim 17, wherein R_2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl, amino, hydroxyalkyl, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino.

Sub
B5

R₈ is amino.

27. The compound of claim 17, wherein A₂ is CR₂, wherein R₂ is other than H and A₁ and A₃ are each CH.


94
cont

28. The compound of claim 17, wherein A₁ is N, A₂ is CR₂, wherein R₂ is other than H and A₃ is CH.

29. The compound of claim 17, wherein A₃ is N, A₂ is CR₂, wherein R₂ is other than H and A₁ is CH.

30. The compound of claim 17, wherein A₂ is N, A₁ is CR₂, wherein R₂ is other than H, and A₃ is CH.

31. The compound of claim 2, having Formula IV:



or a pharmaceutically acceptable salt, prodrug or solvate thereof; wherein:

A₁-A₃, R₂-R₆, and X are as defined in claim 2 and

R₈ is selected from the group consisting of alkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be optionally substituted.

Sub
B6

32. The compound of claim 31, wherein A₁, A₂ and A₃ are each CR₂; or A₁ is N and A₂ and A₃ are CR₂; or A₃ is N and A₁ and A₂ are CR₂; or

Sub B6
A₂ is N and A₁ and A₃ are CR₂; or A₁ and A₃ are N and A₂ is CR₂, and R₂ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl, amino, hydroxyalkyl, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino.

33. The compound of claim 32, wherein R₂ is selected from the group consisting of hydrogen, alkyl, alkoxy, aminoalkyl and aminocarbonyl.

34. The compound of claim 31, wherein R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, and cyano.

35. The compound of claim 34, wherein R₃ and R₄ are both hydrogen and R₅ and R₆ are independently selected from the group consisting of hydrogen, alkyl, halogen, haloalkyl, and nitro.

36. The compound of claim 31, wherein R₈ is selected from the group consisting of alkyl, alkenyl, amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, and heterocycloalkylamino, all of which can be optionally substituted.

37. The compound of claim 31, wherein X is O or S.

38. The compound of claim 37, wherein X is O.

39. A compound of claim 2, wherein said compound is:

4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxamide;

4-[4-(4-nitrophenoxy)phenyl]pyrimidine-2-carboxamide;

4-[4-(4-methoxyphenoxy)phenyl]pyrimidine-2-carboxamide;

4-[4-(4-trifluoromethylphenoxy)phenyl]pyrimidine-2-carboxamide;

Sub
B7

4-[4-(3-chloro-2-cyanophenoxy)phenyl]pyrimidine-2-carboxamide;
4-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-2-carboxamide;
4-[4-(2,4-difluorophenoxy)phenyl]pyrimidine-2-carboxamide;
4-[4-(2-chloro-4-fluorophenoxy)phenyl]pyrimidine-2-carboxamide;
1-[4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-yl]-ethanone;
2-[4-(4-fluorophenoxy)phenyl]pyrimidine-4-carboxamide;
2-[4-(4-fluorophenoxy)phenyl]-4-methylpyrimidine;
2-methyl-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid sodium
salt;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid
methylamide;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid
dimethylamide;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid *tert*-
butylamide;
2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide;
2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxylic acid;
2-(4-phenoxyphenyl)-6-(dimethylamino)pyrimidine-4-carboxylic acid
dimethylamide;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid 2-
hydroxyethylamide;
4-[4-(4-fluorophenoxy)phenyl]pyrimidine-2-carboxylic acid
hydroxymethyleneamide;
2-(2-hydroxyprop-2-yl)-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
4-[4-(2,4-difluorophenoxy)phenyl]pyrimidine-2-carboxylic acid 2-
morpholin-4-yl-ethyl amide;
2-(4,5-dihydro-1H-imidazol-2-yl)-4-[4-(4-fluorophenoxy)phenyl]-
pyrimidine;
2-(3-pyrazolyl)-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;

REF ID: A92880

2-(5-isoxazolyl)-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
2-(1-methyl-3-pyrazolyl)-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxylic acid
methanamide;

3-dimethylamino-1-{4-[4-(4-fluorophenoxy)phenyl]pyrimidin-2-
yl}propenone;

2-thiomethyl-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
2-methanesulfonyl-4-[4-(4-fluorophenoxy)phenyl]pyrimidine;
2-[4-(4-chloro-2-fluorophenoxy)phenyl]-4-methyl-pyrimidine;
4-[4-(4-fluorophenoxy)-3-fluorophenyl]pyrimidine-2-carboxamide;
2-[4-(4-fluorophenoxy)-3-fluorophenyl]pyrimidine-4-carboxamide;
2-methyl-6-(4-phenoxyphenyl)pyridine;
6-(4-phenoxyphenyl)pyridine-2-carboxamide;
2-methyl-6-[4-(4-fluorophenoxy)phenyl]pyridine;
6-(4-phenoxyphenyl)pyridine-2-carboxylic acid;
6-(4-phenoxyphenyl)pyridine-2-carboxylic acid methanamide;
6-[4-(4-fluorophenoxy)phenyl]pyridine-2-carboxamide;
6-[4-(2,4-difluorophenoxy)phenyl]pyridine-2-carboxamide;
6-[4-(4-chloro-2-fluorophenoxy)phenyl]pyridine-2-carboxamide;
6-[4-(4-fluorophenoxy)-3-fluorophenyl]pyridine-2-carboxamide;
6-[4-(4-trifluoromethylphenoxy)phenyl]pyridine-2-carboxamide;
6-(4-phenoxyphenyl)pyrazine-2-carboxamide;
3,5-diamino-6-(4-phenoxyphenyl)pyrazine-2-carboxamide; or
2-[4-(4-nitrophenoxy)phenyl]-4-methyl-[1,3,5]-triazine,
or a pharmaceutically acceptable salt, prodrug or solvate thereof.

40. A compound of claim 1, wherein said compound is:


6-[4-(4-fluorophenoxy)phenyl]pyridine carboxylic acid N-
piperidinylethylamide;

6-(4-*tert*-butylphenyl)pyridine-2-carboxamide;

6-(4-*n*-butylphenyl)pyridine-2-carboxamide;

6-(4-*i*-propylphenyl)pyridine-2-carboxamide;
6-(4-thiomethylphenyl)pyridine-2-carboxamide;
6-(4-ethoxyphenyl)pyridine-2-carboxamide; or
6-(4-methoxyphenyl)pyridine-2-carboxamide,
or a pharmaceutically acceptable salt, prodrug or solvate thereof.

41. The compound of claim 1, having the Formula V:



or a pharmaceutically acceptable salt, prodrug or solvate thereof,
wherein;

A₁-A₃, R₂-R₄, and R₇ are as defined in claim 1; and
X is one of O, S, NH, CH₂ or absent.

42. The compound of claim 41, wherein A₁, A₂ and A₃ are each CR₂; or A₁ is N and A₂ and A₃ are CR₂; or A₃ is N and A₁ and A₂ are CR₂; or A₂ is N and A₁ and A₃ are CR₂; or A₁ and A₃ are N and A₂ is CR₂.

43. The compound of claim 41, wherein R₇ is a C₁₋₆ alkyl optionally substituted with one or more of halogen, hydroxy, nitro, amino, cyano and alkoxy.

44. The compound of claim 41, wherein R₂ is selected from the group consisting of hydrogen, alkyl, alkoxy, aminoalkyl and aminocarbonyl.


46. The compound of claim 45, wherein R₃ and R₄ are both hydrogen.

47. The compound of claim 41, wherein X is O or S.


48. The compound of claim 47, wherein X is O.

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2

50. A pharmaceutical composition, comprising the compound of formula:



or a pharmaceutically acceptable salt, prodrug or solvate thereof,
wherein:



Y is R_6 or R_7 , provided that when Y is R_7 , R_1 is aminocarbonyl;

Sub
B9


DEBATE

X is one of O, S, NH, CH₂ or absent when Y is R₇; and a pharmaceutically acceptable carrier or diluent.


sub
A2

51. The composition of claim 50, wherein the compound is as claimed in any one of claims 1-49.

52. A method of treating a disorder responsive to the blockade of sodium channels in a mammal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula:



or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:



Y is  or R7,

provided that when Y is R7, R6 is aminocarbonyl;

A₁, A₂ and A₃ are independently CR₂ or N, provided that A₁, A₂ and A₃ are not all N at the same time;

R₁ is selected from the group consisting an optionally substituted alkyl, amino, alkylthiol, C(O)R₈, SO₂R₈, OC(O)NH₂, 2-imidazolyl, 2-imidazolyl, 3-pyrazolyl, 5-isoxazolyl, and 3-(1,2,4)-triazolyl;

each R₂ is selected from the group consisting of hydrogen, optionally substituted alkyl, alkenyl, or alkynyl, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; or R₁ and R₂ are taken together with the carbon atoms to which they are attached to form a heterocyclic ring;

R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido, acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R₇ is an optionally substituted alkyl;

R₈ is selected from the group consisting of alkyl, alkenyl, alkynyl, OR₉, amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be optionally substituted, provided that R₈ is not OR₉ when R₁ is SO₂R₈; wherein


R₉ is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkali metal; and

X is one of O, S, NH, or CH₂ when Y is other than R₇; or


X is one of O, S, NH, CH₂ or absent when Y is R₇.

53. The method of claim 52, wherein the compound administered is as claimed in any one of the claims 1-49.

54. A method for treating, preventing or ameliorating neuronal loss following global and focal ischemia; treating, preventing or ameliorating neurodegenerative conditions; treating, preventing or ameliorating pain or tinnitus; treating, preventing or ameliorating manic depression; providing local anesthesia; or treating arrhythmias, or treating convulsions, comprising administering to a mammal in need of such treatment an effective amount of a compound formula:



or a pharmaceutically acceptable salt, prodrug or solvate thereof,
wherein:



Y is or R₇,

provided that when Y is R₇, R₁ is aminocarbonyl;

A₁, A₂ and A₃ are independently CR₂ or N, provided that A₁, A₂ and A₃ are not all N at the same time;

R₁ is selected from the group consisting an optionally substituted alkyl, amino, alkylthiol, C(O)R₈, SO₂R₈, OC(O)NH₂, 2-imidazolyl, 2-imidazolyl, 3-pyrazolyl, 5-isoxazolyl, and 3-(1,2,4)-triazolyl;

each R₂ is selected from the group consisting of hydrogen, optionally substituted alkyl, alkenyl, or alkynyl, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; or R₁ and R₂ are taken together with the carbon atoms to which they are attached to form a heterocyclic ring;

R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido, acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R_7 is an optionally substituted alkyl;

R_8 is selected from the group consisting of alkyl, alkenyl, alkynyl, OR_9 , amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be optionally substituted, provided that R_8 is not OR_9 when R_1 is SO_2R_8 ; wherein

R_9 is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkali metal; and

X is one of O, S, NH, or CH_2 when Y is other than R_7 ; or


X is one of O, S, NH, CH_2 or absent when Y is R_7 .

Sub
A4


55. The method of claim 54, wherein the compound administered is as claimed in any one of claims 1-49.

56. The method of claim 54, wherein the method is for treating, preventing or ameliorating pain and said pain is one of neuropathic pain, surgical pain or chronic pain.

57. A method of alleviating or preventing seizure activity in an animal subject, comprising administering to said animal in need of such treatment an effective amount of a compound of formula:



or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:



provided that when Y is R₇, R₁ is aminocarbonyl;

A₁, A₂ and A₃ are independently CR₂ or N, provided that A₁, A₂ and A₃ are not all N at the same time;

R₁ is selected from the group consisting an optionally substituted alkyl, amino, alkylthiol, C(O)R₈, SO₂R₈, OC(O)NH₂, 2-imidazolyl, 2-imidazolyl, 3-pyrazolyl, 5-isoxazolyl, and 3-(1,2,4)-triazolyl;

each R₂ is selected from the group consisting of hydrogen, optionally substituted alkyl, alkenyl, or alkynyl, halogen, hydroxy, cycloalkyl, cyano, amino, alkylamino, dialkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and aralkylcarbonylamino; or R₁ and R₂ are taken together with the carbon atoms to which they are attached to form a heterocyclic ring;

R₃, R₄, R₅, and R₆ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido, acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R₇ is an optionally substituted alkyl;

R₈ is selected from the group consisting of alkyl, alkenyl, alkynyl, OR₉, amino, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, dialkylaminoalkylamino, dialkylaminoalkenylamino, alkylaminoalkenylamino, hydroxyaminoalkenylamino, cycloalkyl, heterocycloalkyl, cycloalkylalkylamino, heterocycloalkylamino, aryl, arylalkyl, arylalkenyl, arylalkynyl, and arylalkylamino, all of which can be optionally substituted, provided that R₈ is not OR₉ when R₁ is SO₂R₈; wherein

13

~~A~~
~~hod c~~

A hand-drawn diagram of a triangle. The top vertex is labeled 'b', the bottom-left vertex is labeled 'a', and the left side is labeled '5'.

58. The method of claim 57, wherein the compound administered is as claimed in any one of claims 1-49.

Add
B10

add
C7